Results of the BELLE-3 study of buparlisib for advanced breast cancer

Share :
Published: 14 Dec 2016
Views: 2807
Rating:
Save
Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA

Dr O'Regan speaks with ecancertv at SABCS 2016 about the outcomes of the phase III BELLE-3 trial, in which post-menopausal women with advanced or metastatic HR positive breast cancer who had disease progression during or after mTOR inhibitor therapy were treated with buparlisib and fulvestrant.

While the combination improved progression free survival at 6 months, as gauged by PIK3CA status, she notes the dose reductions and adverse events among a small number of patients in the trial, including incidences of depression and suicidal ideation.